| |
Title: |
 |
Potential of small molecule protein tyrosine kinase inhibitors as immuno-modulators and inhibitors of the development of Type 1 diabetes |
|
| |
Authors: |
|
Little, Peter J. ; Cohen, Neale ; Morahan, Grant |
|
| |
Journal: |
|
TheScientificWorldJOURNAL |
|
| |
Year: |
|
2009 |
|
| |
Volume: |
|
9 |
|
| |
Page Range: |
|
224-228 |
|
| |
Article Type: |
|
Directions in Science |
|
| |
Handling Editor: |
|
Lawrence A. Frohman |
|
| |
Domains: |
|
Endocrinology
,
Drug Discovery
,
Cell Signaling
,
Immunology & Inflammation
,
Metabolism & Metabolic Disease
,
Medicine
,
Biochemistry & Molecular Biology
|
|
| |
DOI: |
|
10.1100/tsw.2009.28 |
|
 ?
|
animals -
anticancer agent -
autoimmune disease -
case studies -
chronic myeloid leukemia -
diabetes -
human case -
hyperglycemia -
imatinib -
immunomodulatory effects -
insulin -
juvenile onset diabetes -
leukemia -
mouse models -
prevention of diabetes -
protein tyrosine kinase -
target -
type 1 diabetes -
tyrosine kinase inhibitor
|
| |
Synopsis: |
|
Type 1 (previously insulin dependent or juvenile onset) diabetes is an auto-immune disease for which there is no current prevention or cure. The anti-cancer agent and protein tyrosine kinase inhibitor imatinib is used successfully in the treatment of chronic myeloid leukaemia. Imatinib has shown a variety of immunomodulatory effects in animals and humans and it has recently been reported to inhibit the development of hyperglycaemia in two unrelated mouse models of diabetes and in one human case study. Although the biochemical target has not been characterised, potentially this represents a major advance for the treatment and prevention of diabetes. |
|
| |
Keywords: |
|
Type 1 diabetes, Type 2 diabetes, imatinib, autoimmunity, NOD mouse |
|
| |
|
|
|
|
| |
|
|
![[Full Text PDF]](../images/pdf.gif "Download Full Text PDF")
[Related TSW Articles]
[Export to EndNote]
[Open Choice]
|
|
| |
|
|
|
|
| |
|
|
Abstract |
|
| |
|
|
Type 1 diabetes (previously insulin-dependent or juvenile-onset diabetes) is an autoimmune disease for which there is no current prevention or cure. The anticancer agent and protein tyrosine kinase inhibitor imatinib is used successfully in the treatment of chronic myeloid leukemia. Imatinib has shown a variety of immunomodulatory effects in animals and humans, and it has recently been reported to inhibit the development of hyperglycemia in two unrelated mouse models of diabetes and human case studies. Although the biochemical target has not been identified, potentially this represents a major advance for the treatment and prevention of diabetes. |
|
| |
|
|
Related articles in:
|
|
| |
|
|
|
|
| |
|
|
| |
Post Your Comment |
 |
|
|
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|